News | Antiplatelet and Anticoagulation Therapies | April 16, 2019

HonorHealth Research Institute Launches SynIVUS-DAPT Study

Study will investigate benefit of shortening dual antiplatelet therapy duration for patients at high bleeding risk after coronary stent implantation

HonorHealth Research Institute Launches SynIVUS-DAPT Study

April 16, 2019 — HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical study is designed to test outcomes of decreasing the amount of time patients with a high risk of bleeding take antiplatelet medications after receiving a drug-eluting coronary stent.

"People who receive drug-eluting stents are required to take antiplatelet medications for six to 12 months after stent placement," said David G. Rizik, M.D., chief scientific officer and director of structural and coronary interventions at HonorHealth Research Institute and principal investigator for the study. "These medications can exacerbate bleeding risk and therefore, being able to reduce the amount of time patients are on these dual antiplatelet regimens can be beneficial."

All five HonorHealth hospitals in the greater Phoenix area are participating in the study. Two other hospital systems also are participating:

  • Massachusetts General Hospital, under the direction of Farouc Jaffer, M.D., Ph.D., FACC, FAHA, FSCAI, director, coronary intervention and chronic total occlusion PCI program; associate physician, Massachusetts General Hospital (MGH) Cardiology, Department of Medicine; associate professor of medicine, Harvard Medical School; and
  • Northwell Hospital System in Long Island, N.Y., under the direction of Varinder P. Singh, M.D., FACC, FSCAI, chairman, Department of Cardiovascular Medicine Lenox Hill Hospital, Northwell Health; senior vice president, cardiology service line Northwell Health, Western Region.

Individuals in this study have developed a blockage in one or more arteries in their heart which may require a drug-coated stent to open the blockage(s). The study also uses an imaging procedure called intravascular ultrasound (IVUS) at the time of stent placement. The IVUS procedure looks at the placement of the stent to make sure it is fully opened and against the artery wall.

Individuals considered at high risk for bleeding include those who:

  • Are 75 and older;
  • Require blood-thinning medications for health issues such as blood clots or an irregular heart rhythm;
  • Have had a stroke; and
  • Are at risk for falling or other conditions that may put them at a high risk of bleeding.

For more information: www.honorhealth.com

Related Content

Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init